Champions Oncology announces $2 million award from the National Cancer Institute (NCI) to develop and evaluate prostate cancer PDX models

Sep 26, 2017 2:53:02 PM / by Mark Weinstein

HACKENSACK, NJ - September 26, 2017 - Champions Oncology, Inc. (NASDAQ : CSBR) a company engaged in the development and sale of advanced technology solutions and products to personalize the development and use of oncology drugs, today announced the signing of a competitive contract through the government’s Small Business Innovation Research (SBIR) program. The contract is in response to Topic 355 – Cell and Animal-Based Models to Advance Cancer Ethnic Health Disparity Research. Champions’ direct-to-Phase II proposal, entitled “Metastatic Prostate Cancer Patient Derived Xenograft Modeling; A New Operating Paradigm”. The contract is a 2-year, $2 million project.  Champions’ network of collaborating sites will contribute to this project.

The project will build and study an ethnically diverse cohort of metastatic prostate patient-derived xenograft (PDX) models.  Fully characterized, ethnically diverse prostate PDX models are under-represented among PDX banks, limiting opportunities for pre-clinical and translational oncology studies.  Not only is the incidence of prostate cancer higher in African American men than other ethnic groups, the mortality rates from prostate cancer for African American men are higher. A primary goal of this project is to create new tools to better understand the ethnic health disparity in prostate cancer.

The project will leverage Champions’ current quality management strategies for industrial scale PDX development and incorporate novel approaches and techniques to efficiently build and study new prostate PDX models.  Champions has partnered with InnoGenomics, a molecular diagnostics technology innovator, to apply their proprietary, high-sensitivity liquid biopsy techniques to PDX models.

"We are very excited that the NCI has chosen Champions for this SBIR award and has recognized Champions’ expertise in quality management systems for commercializing the development of these models”, said Angela Davies, MD., Chief Medical Officer of Champions Oncology. “This award allows us to dramatically expand our prostate PDX program and demonstrate the benefits of new techniques and approaches that advance the field.”

CEO Ronnie Morris added, “This award highlights the significant opportunities we are creating for ourselves and our partners through strategic and focused investments in key R&D activities.”

The ethnically diverse prostate PDX models will be fully characterized and annotated. In addition to clinical, molecular and histological characterization of each model, standard-of-care drug testing will be performed. The models and associated data and information will be shared with the NCI to further research in prostate cancers.

About Champions Oncology

Champions Oncology, Inc. is engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs. The company's technology platform is a novel approach to personalizing cancer care based upon the implantation of primary human tumors in immune-deficient mice to create TumorGrafts that preserve the biological characteristics of the original human tumor to determine the efficacy of a treatment regimen. The company uses this technology in conjunction with related services to offer solutions for two customer groups: Personalized Oncology Solutions, in which results help guide the development of personalized treatment plans, and Translational Oncology Solutions, in which pharmaceutical and biotechnology companies seeking personalized approaches to drug development can lower the cost and increase the speed of developing new drugs. For more information, please visit

Investor Contact

Brett Maas
Hayden IR
(646) 536-7331

James Carbonara
Hayden IR